Medical Device Stock Disrupting a Billion Dollar Industry

0
587

This Revolutionary Start-Up Aims to Stop the No.1 Killers World-Wide via a Revolutionary, Simple, Effective & Personalized Early Detection Technology

*GROUND FLOOR OPPORTUNITY*


Big name companies like Apple (AAPL) & Alphabet (GOOGL) are making their way into the healthcare sector. With their expertise and ample resources it can change the industry completely in a great way & potentially provide ample buy-out opportunities for companies like: Lexington BioSciences (CSE: LNB) (OTC: LXGTF)



THE PROBLEM:
Heart Disease & Stroke are the No.1 Killers World-Wide.

Nearly 1 in 3 deaths in the USA are caused by heart disease and stroke.

Of the approximately 1.5 million people suffering heart attacks annually in the U.S., more than 250,000 will die within one hour of their incident.

Nearly 1/3 of the ~ 600,000 annual cardiovascular disease deaths in the U.S. could be prevented through changes in lifestyle habits.

Unfortunately, for up to 50% of these individuals, the FIRST SYMPTOM of coronary artery disease is sudden cardiac death, or a heart attack.
-Source: World Health Organization / Center for Disease Control (CDC) Atlanta,

Atherosclerosis is the most common cause of death in developed countries. It is the deposition of cholesterol and fatty material, or plaque deposits, on the inner walls of arteries. Most heart attacks and strokes are caused by these fatty deposits breaking free of the artery wall, then lodging downstream and blocking blood flow.

Early detection is key to prevention through a proactive lifestyle via physician care and ongoing monitoring. However, blood pressure and cholesterol monitoring are only partial indicators of cardiovascular health. Most cardiovascular disease is related to plaque buildup and inflammation within the arteries.


Don’t Forget to Join our FREE Text list! From Your Cell Phone Text the Phrase TECHSTOCKS to 474747


SOLUTION: EARLY DETECTION

The only way to detect that arteries are vulnerable to atherosclerosis is to assess endothelial function. This is a test of the endothelial cells that line all the arteries in the body. The endothelium which is the single layer of cells that line various organs and cavities, especially the heart, blood and lymphatic vessels. These cells act as a shield, preventing plaque from forming inside the artery wall, and produce substances that stop blood clots from developing in the vessel.

Healthy endothelial cells release nitric oxide, which is responsible for most of the protective functions of these cells in the artery.

CURRENT DETECTION TECHNOLOGY

Today, diagnostic candidates must consult with their physician, book an appointment, and visit a specialized facility to undergo an assessment with a trained technician.

The current standard for arterial endothelial assessment requires a visit to a diagnostic center where a technician employing a high-resolution ULTRASOUND imager will take approximately an hour to perform the diagnostic measurements.

OPPORTUNITY IS KNOCKING:

By 2020, $2.6 billion Global monitoring instruments market will increasingly shift to the high-growth home segment.

Lexington BioSciences (CSE: LNB) (OTC: LXGTF)
is revolutionizing  the healthcare marketwith a product first in class to monitor vascular health and detect cardiovascular disease even at a premature stage, the Cardiovascular Diagnostic Medical Device. HealthSentry(tm) is a revolutionary, simple, effective & personalized technology that is poised to save lives!

Heart Sentry

 


Don’t Forget to Join our FREE Text list! From Your Cell Phone Text the Phrase TECHSTOCKS to 474747


THE ANSWER:

heartsentry

HeartSentry™ has been developed by Lexington BioSciences (CSE: LNB) (OTC: LXGTF)
to measure the function of the endothelium, the cells that line all arteries and are critical to the prevention of atherosclerosis, heart attacks and stroke.

HeartSentry’s™ targets the rapidly growing self-measurement medical device sector and is designed for both personal and clinical use. Simplicity and functionality are key elements of the design.

Designed to efficiently measure increases in arterial volume which occur when the endothelial cells of the artery are stimulated, and the muscles in the wall of the artery relax.

HeartSentry™ has been extensively tested to measure the function of the endothelium, the cells that line all arteries and are critical to the prevention of atherosclerosis, heart attacks and stroke, the two leading causes of death worldwide with over 17.5 million deaths each year. The unit is designed to communicate via Bluetooth technology to provide up-to-date and accurate readings of an individual’s complete cardiovascular health through electronic monitoring for cardiovascular risk-assessment and to aid treatment effectiveness for the prevention of heart attack and stroke.

How HeartSentry™ Works

Lexington BioSciences’s (CSE: LNB) (OTC: LXGTF) proprietary HeartSentry™ inflatable cuff utilizes specialized algorithms to interpret changes in the volume of blood in the arm. In a relaxed, dilated artery, the volume change over the cardiac cycle is much greater than baseline levels, typically by more than 80% in healthy subjects.

The fully automated device is compact and inexpensive enough for commercial use in the home care market and primary care physician offices. Its integrated Bluetooth technology can communicate with nearby smart applications which can act as a portal to cloud-based technologies enabling advanced ongoing monitoring opportunities between patient and clinical care providers. There is a potential for generated data to be valuable to bioinformatics providers. Integration with additional data streams allows further predictive ability for assessing cardiovascular disease progression.

HeartSentry™ is a combination device that measures BOTH blood pressure and endothelial function. This ADDED FEATURE increases the value and interest in purchasing a blood pressure and endothelial function monitoring device, and is designed to deliver a more accurate picture of cardiovascular health.

heartsentry competition

 

HeartSentry™ DEVELOPMENT PLAN

  • Develop regulatory plan and meet with FDA to confirm
  • Create test platform for algorithm development
  • Establish scientific advisory board
  • Create quality system
  • Identify and sign contract with manufacturing partner
  • Manufacture units
  • Acute calibration study
  • Clinical study comparing cFMD to uFMD (or other standard) and show positive correlation AND LAST BUT NOT LEAST…

Submit for FDA approval with calibration study data

According to Lexington BioSciences (CSE: LNB) (OTC: LXGTF)
 the Company has communicated with the FDA its strategic plan for a 510(K) submission. Lexington BioSciences has explained that interactions with the FDA to date have been positive and collaborative, providing increased confidence with their chosen regulatory and testing strategies.


Top Leaders are on Board TO SECURE SUCCESS

The principals, directors and advisors of Lexington BioSciences (CSE: LNB) (OTC: LXGTF) have been individually and collectively involved in raising extensive capital funding for their private and public companies. Team members have held numerous executive leadership positions encompassing biotechnology, and medical device companies, as well as multi-national corporations. The team includes inventors, scientists, and business people who have successfully started, built and grown multiple life science companies.

Eric Willis, Chief Executive Officer

eric LXGTF CEOMr. Willis is an entrepreneurial healthcare technology executive with a track record of success in bringing products from initial concept to market. He is the past President and Chief Operating Officer of ParaPatch (2013–2015), where he was responsible for the development and launch of an over-the-counter women’s health product for the treatment of urinary incontinence. Prior to this, he served as President and CEO of InSite Medical Technologies (2008–2013) a venture backed start-up medical device company that developed a new method for performing epidural anesthesia. From 1994–2008 he served in a variety of executive and operational roles for cardiovascular medical device companies.

Rocco Rossi, Director

A successful entrepreneur and business executive, champion fundraiser, and Rocco-Rossidedicated public servant, Rocco Rossi is currently President and CEO of Prostate Cancer Canada. His unique blend of experience intersects general management, philanthropy, public policy, politics, business strategy, and new media. As CEO of the Heart and Stroke Foundation – one of Canada’s largest non-profit organizations – from 2004 to 2009, Rossi oversaw four consecutive years of record fundraising raising over $500 million in total and launching many new, life-saving initiatives. His passion for public policy has led him to stand for election both for the position of Mayor of Toronto and for MPP.

Doug Janzen, Chairman

Doug LXGTFMr. Janzen has 20 years of experience in life sciences with leadership experience in corporate finance, business development, and operational management of life sciences companies. Mr. Janzen is currently Co-Founder and Managing Director of Northview Ventures. He serves as Chairman and CEO of Aequus Pharmaceuticals (AQS-TSXV), a company that was founded within Northview. Prior to Northview Ventures, he was President and CEO of Cardiome Pharma (NASDAQ: CRME) During this time he raised over $300 million from investors, completed over $1 billion in licensing deals.

Greg Robertson, M.D., Medical Advisor

robertson-gregory LXGTFDr. Greg Robertson is chief of the Emory Heart and Vascular Clinic at Johns Creek. At the Emory Johns Creek Hospital he is chief of cardiology and the medical director of the cardiac catheterization laboratory and interventional program. He is board certified in Vascular Medicine, Endovascular Medicine, Interventional Cardiology and Cardiovascular Medicine. He is an associate professor of medicine at Emory University. Dr. Robertson’s clinical expertise has focused on preventative care and using minimally-invasive vascular and cardiac treatment.


The Next Chapter In Health CARE  TechNOLOGY Is Happening NOW

google headquarters alphabet

Alphabet (GOOGL) with a market cap of $635.96 billion has a current share price of more than $950. Verily is their new wearable a study watch that captures health data. According to the post, the watch represents efforts to create, “new tools for unobtrusive biosensing”.

Apple (AAPL) with a market cap of 728.30 billion and current share price of over $140 has the Apple Watch. The Series 1 launched in 2015 and was the world’s best selling wearable that year with 4.2 million sold in the second quarter of 2015. Apple apple watch stockreported the “best quarter ever” in the wearable technology market.

Dexcom (DXCM) with a market cap of $6.09 billion has a current share price over $70. It has a medical device company and designed glucose monitoring (CGM) systems for those with diabetes and for healthcare providers. Dexcom now has its fifth generation CGM system, Dexcom G5 Mobile CGM system, which utilizes Bluetooth technology built into the transmitter.

Dexcom glucose monitor stockWith huge leaders in the industry continuing to grow and develop in the wearable medical device market why not take advantage when you can before it’s too late.
As you can see, the industry has immense potential.

It isn’t every day that you see companies like Apple and Alphabet investing billions of dollars into the space.

Lexington BioSciences (CSE: LNB) (OTC: LXGTF) has created a unique platform to take advantage of the industry growth in a niche that could be set to carve its own marketplace. Meanwhile, the timing of this could be very important for those looking for a near term opportunity.


Ready for More Info on (LXGTF)?


TechStockInsider.com is owned by Midam Ventures, LLC has been compensated $100,000.00 by Ellis Stewart, LLC for a period beginning October 1, 2017 and ending November. 1, 2017 & Midam Ventures, LLC has been compensated an additional $150,000.00 by Ellis Stewart, LLC for a period beginning November 1, 2017 and ending December. 1, 2017 & Midam Ventures, LLC has been compensated an additional $150,000.00 by Ellis Stewart, LLC for a period beginning December 1, 2017 and ending December 31, 2017 to publicly disseminate information about (LXGTF). We may buy or sell additional shares of (LXGTF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. We own zero shares.

Click Here For Full Disclaimer.



LEAVE A REPLY

Please enter your comment!
Please enter your name here